Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

02/11/2013 | 10:44am US/Eastern
   By Melodie Warner 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at

Subscribe to WSJ:

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
Recommend :
React to this article
6d ago REGENERON PHARMACEUTICALS : Announces Submission of Application for EYLEA® aflib..
6d ago REGENERON PHARMACEUTICALS : Patent Application Titled "Genetically Modified Majo..
7d ago REGENERON PHARMACEUTICALS : Biotech Stocks Under Review -- Keryx Biopharma, Sang..
09/08 NASDAQ 100 MOVERS : Regn, yhoo
09/07 REGENERON PHARMACEUTICALS : and Sanofi Updates on Positive Results from 4 Aliroc..
09/04 REGENERON PHARMACEUTICALS : Patent Issued for Conditioned Culture Media
09/04 NASDAQ 100 MOVERS : Spls, fast
09/04 REGENERON PHARMACEUTICALS : Announces Submission of Application for EYLEA® (afli..
09/04 REGENERON PHARMACEUTICALS : and Sanofi Reports Positive Results from 4 Alirocuma..
09/02DJMARKET SNAPSHOT : S&P 500 Falls Back Under 2,000 As Stocks Slip
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
Regeneron Pharmaceuticals  : Income Statement Evolution
More Financials
Dynamic quotes